Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for KIT exon 11-mutant GIST, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Whether adjuvant imatinib should continue for five years or longer.
Resistance through secondary KIT mutations in nearly every metastatic patient.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Tumours that recur after stopping adjuvant therapy despite years of control.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 6 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.